Page 3 of 33 https://docs.google.com/spreadsheet/gform?key=0Aq_l0aMh4cwrdGZscXJBMGVRZDZWVjRSaWl0QzFVSFE&hl=en_US&gridId=0#chart 1a-iii) Primary condition or target group in the title subitem not at all importantessential 1 -subitem not at all important 0 0% 2 0 0% 3 3 5% 4 18 33% 5 -essential 31 56% Comment on subitem 1a-iii) If primary condition/target group is not mentioned in the title, it is absolutely essential to mention in the abstract. I would recommend requiring both primary condition AND the target group. If the title becomes too long with the target group(my RCT was directed to generally healthy adults), this should be clearly described in the abstract and manuscript. I think it is important to phrase in terms of the WHO ICF. An mobile EHR with tablet PC support for patients with mental disabilities Essential to allow for future comparisons across studies and allow the possibility of being part of meta-ana ...
INTRODUCTION https://docs.google.com/spreadsheet/gform?key=0Aq_l0aMh4cwrdGZscXJBMGVRZDZWVjRSaWl0QzFVSFE&hl=en_US&gridId=0#chart 2b) Specific objectives or hypotheses (note: Contrary to STARE-HI we do not recommend to mention IRB approval in this section -JMIR and other journals typically recommend this as a subheading under "methods". CONSORT-EHEALTH has a separate item for ethical considerations)
(no EHEALTH-specific subitems under CONSORT item 2b)
I assume there is, however, a requirement for specific objectives. Essential to allow for future comparisons across studies and allow the possibility of being part of meta- 
METHODS 3a) Description of trial design (such as parallel, factorial) including allocation ratio (no EHEALTH-specific subitems under CONSORT item 3a)
I agree, this is often too complex to perform in ehealth trials That will be mentioned except for the allocation ratio because the allocation was coded randomized during the programming process (and normally it is not a rule to provide the algorithm) mere mention of the design and allocation ratio would be ideal. would expect to be reported if they were significant, so major breaks should be reported. However, major changes to functionality or content or design would be essetial to report (score 5) Authors should mention if new content was added to system during the trial. In my opinion this is often the case. Essential to https://docs.google.com/spreadsheet/gform?key=0Aq_l0aMh4cwrdGZscXJBMGVRZDZWVjRSaWl0QzFVSFE&hl=en_US&gridId=0#chart allow for future comparisons across studies and allow the possibility of being part of meta-analyses Such change events can be represented in a timeline fashion. I think that "u ...
Add a subitem under CONSORT item 3b
Brief description of website layout and complexity ("After a brief welcome screen, participants enter their weight and length and proceed to the food diary in the taskbar etc.") More specifics regarding the software used during the interventions and whatever was used for analysis. After completion of trials, there may be a "lag" time for researchers to prepare and publish the results of their study. It may happen that the version(s) of the solutions used at the time of study design and conduct, change during this "lag" time. The discussion on these kinds of "version" changes seems necessary. T ... 
4a) Eligibility criteria for participants

Comment on subitem 4a-i)
Only to be stated and assessed if there is reason to suspect that a target group may be illiterate in the world of technology. For example, studying a group of ADHD patients where dyslexia is a highly prevalent condition or older participants with age >60 years. I consider this part of the needs assessment and this should only be mentioned in the discussion section if this appears to be a problem. Low importance in open trials e.g. users have found the site.
However, in closed trials this may be an important factor e.g. if they are referred to the site for treatment. In both types of trial, t ...
4a-ii) Open vs. closed, web-based vs. face-to-face assessments:
subitem not at all importantessential 1 -subitem not at all important 0 0% 2 0 0% 3 3 5% 4 14 25%
5 -essential 35 64%
Comment on subitem 4a-ii)
An important point is that it may be extremely difficult or even impossible for researchers to have a complete overview of the entire recruitment process due to the fact that, at least, the Internet is a medium which is hard to control. One such https://docs.google.com/spreadsheet/gform?key=0Aq_l0aMh4cwrdGZscXJBMGVRZDZWVjRSaWl0QzFVSFE&hl=en_US&gridId=0#chart
example which serves to identify many of the problems I mention is viral recruitment where a researcher uses his or others' social networks to recruit participants. The researcher can control his 1st degree contacts, but this is hardly possible for 2nd, 3rd... degree contacts. That is simply the nature of online viral recruitment. This is similar to ...
4a-iii) Information giving durnig recruitment
subitem not at all importantessential Comment on subitem 4b-i) Data collection instruments and methods should be described I would ask for clarification on 1) the assessment medium (online, mail, telephone interview, etc.) and 2) perspective (self-report, interviewer, etc.) If possible, comment on how successful the adaptation of an existing pen-and-paper to an online questionnaire was (e.g., visual analogue scale required with pen-and-paper test but was not available in online questionnaire software, etc.) Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Essential Details of pilot-testing of ...
4b-ii) Report how institutional affiliations are displayed
subitem not at all importantessential 
Comment on subitem 4b-ii)
This is common to face-to-face interventions where universities / hospitals may be regarded as more trust worthy than drug companies. This is the issue of the credibility of website or mobile intervention. It is not unique to ehealth (a pharmacotherapy trial by Harvard may be perceived differently than one run out of a private practice). This seems to be adding a new criterion category. Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses A very nice idea This is an interesting aspect, however, I don't think it's an essential item. W ...
Add a subitem under CONSORT item 4b
If not self-assessed, it is needed to describe (a) how participants were assessed and (b) whether this was problematic given the setting of a web-based intervention. Are online questionnaire metrics reported, and how were "unlikely" questionnaire metrics handled (e.g., were questionnaires that were answered unusually quickly included (indicative of participant inattention or laziness)) I am not sure if this is the right heading for this item.
However, to my opinion it is important to state how participants got to know about the intervention. How was it spread/promoted to potential users? Often ...
5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
5-i) Mention names, credential, affiliations of the developers, sponsors, and owners
subitem not at all importantessential Comment on subitem 5-ii) Essential unless these were published previously elsewhere. Including a logical/process model of the intervention, for example in a flow chart, would really enhance the publications. It may be necessary to add this in an appendix. There should preferrably be some guidelines on how to develop a logical/process model. This is very important to for designers, practitioners, and academics to learn more about the success/pitfalls of intervention design and development. Also describe how formative evaluations shaped the intervention. If these are not previously published, I'm not sure that saying " ...
5-iii) Revisions and updating
5-vi) Digital preservation
Comment on subitem 5-vi)
As with publishing the source code, it is not always possible to digitally archive an intervention. Again, sufficient detail should be provided to enable readers to understand all the components of the intervention to replicate or build upon prior work. If this is a funded research project, the URL will be inactive by the time the manuscript is published. This digital preservation is not likely or even possible in many cases. It would be a "demo" only -which is not very helpful. see my comment above. Essential to allow for future comparisons across studies and allow the possibility of being ...
5-vii) Access
subitem not at all importantessential
Comment on subitem 5-vii) "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes..)" This would be absolutely wonderful. Participant access needs to be described -essentail (score 5) This item seems to confound participant access and reviewer access. I think separating out the requirements of reporting about the intervention from the methods of disclosure would clarify. Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Essential Any specific constraint in access should be discussed;
fo ...
5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework
Comment on subitem 5-ix)
Yes! If there is paradata available, also report the extent to which intended doses compared with actual use. exposure is very important!! Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Essential I think a few measures of COMPLIANCE to the intervention should be mentioned in this part as an example. I imagine this would be reported as needed, and doesn't need to be a guideline.
In the intervention section only, can be showcased with a pictorial representation or a flow diagram. idem This is an important point but may very likely to b ...
5-x) Clarify the level of human involvement
Comment on subitem 5-x) Also, identify any manuals, procedures or principals used in guiding the human support. this might especially provide important information for implementation strategies of ehealth interventions. It might be that in the beginning more human involvement is needed. Essential to allow for future comparisons across studies and allow the possibility of being part of metaanalyses Essential High-risk alerts of participants that may harm themselves etc. and how these were dealt with (automated, human-intervention etc).
In the intervention section. idem Clear explanation is required, as this item can be s ... The content of the prompts is also essential. Prompts may be extremely reinforcing the use of the intervention. Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Very important These ways of reminding have different effects in different contexts and for different interventions. How one can assure the re ...
5-xi) Report any prompts/reminders used
5-xii) Describe any co-interventions (incl. training/support)
Add a subitem under CONSORT item 6a
It might be that also some unexpected side effects could be detected.
researchers should acknowledge the value of this for the young ehealth research field. These should also be stated when encountered.
-No.
6b) Any changes to trial outcomes after the trial commenced, with reasons (no EHEALTH-specific subitems under CONSORT item 6b)
researchers should acknowledge the value of this for the young ehealth research field. These should also be stated when encountered. It could provide important clues for future trials what we could expect to be outcomes of an intervention.
Will be obviously Comment on subitem 11a-i) Yes. FYI -I've seen growing numbers of journals ask for the work "masking" since blinding is purportedly pejorative. I would also ask that if an assessment of the effectiveness of blinding was performed, that it be provided.
(patients often mention their tx assigment to evaluators -it is important to know if that was monitored and if so, how it was managed when it occured). Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Essential Any effects of "non-blinding" on the possible outcomes of the study, should be discussed or at le ... 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"
Comment on subitem 11a-ii)
This is the same as a face-to-face trial. This is an important issue. But it is setting a higher level for ehealth than other areas. Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Essential !!! Challenges on developing "sham" e-interventions, "placebo" e-intervention or the "comparator" e-intervention (if appropriate) should be discussed. Now it involves skills as to generate a program which wont let the participants guess. mention in the methodology section. This could be associated to a form of "blinding" Unlike medication, when t ...
Add a subitem under CONSORT item 11a
11b) If relevant, description of the similarity of interventions
(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)
(no EHEALTH-specific subitems under CONSORT item 11b)
Surely it is relevant -eg. were the intervention and comparitor of similar intensity? did they require the same 
Add a subitem under CONSORT item 12a
In the case of clustered randomized trials and repeated measurements, reserachers should be required to conduct multilevel analysis. It is a too common statistical mistake to conduct single-level analysis in cases where there are two or more levels of data. For example, time-level data which are repeatedly measured and person-level data which are measured on one occasion (typically baseline) in a repeated measurements study design. Otherwise, one runs the risk of getting entirely wrong results and drawing wrong conclusions. Include statistical procedures used and why they were chosen -No. 
12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses
X26-iii) Safety and security procedures
RESULTS
13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center
(no EHEALTH-specific subitems under CONSORT item 13a)
Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Any specific method for analysis should be mentioned. For example "intention to treat" etc. Via a Flow Chart or a pictorial representation. No.
Number of people *in each analysis*. This is frequently unclear and the number of people in each analysis is essential for calculating an effect for meta-analysis. However, this isn't unique to e-health.
13b) For each group, losses and exclusions after randomisation, together with reasons 13b-i) Attrition diagram
Comment on subitem 13b-i)
An interesting contrast to drug trials -where self-report or pill count is all that is often done to evaluate 'adherence' with treatment. I would distinguish attrition from intervention from lost-to-follow-up from assessment.
Specify both drop-out and non-use attrition separately We did not have any way to collect reasons for discontinuing participation -as we had no contact with our participants other than email/online intervention. We had no IRB permission to request details of discontinuing participation. There are many cases in which reasons for attrition would be available. Essential to ...
Add a subitem under CONSORT item 13b
Describe whether there was differential attrition (i.e., a differences in attrition between the two groups) and how was dealt with this. It is covered above under methods, but I would have use data here. It is really important to report a clear metric for use, separate from attrition. Someone who logs into a site every day over 12 weeks has a different dose from someone who logs in once every week. And I suspect this will be important to systematic reviewers in the future. 5 -essential 20 36%
Comment on subitem 14a-i)
Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Japan is a recent example. Experiment wise, in the methodology section. only month and year would be enough. it's a co-intervention related to 3bi and 5iii Good point. However, if these events have been described in the "Method" section, it is probably a redundant to mention it again in the "Results" section here. I can see how this is important, but I'm not sure it's essential.
Add a subitem under CONSORT item 14a
Would this include events like Hurricane Katrina or 9/11, in which cases people would rather watch television that use a web-based intervention.
14b) Why the trial ended or was stopped (early) (no EHEALTH-specific subitems under CONSORT item 14b) this could also be the case in ehealth trials. So I would not omit this item from this checklist. Yes, this is would be important to include in case anyone else may want to try and replicate the study Reason should be quoted in the discussion. No.
EHEALTH-specific additions here: Secular events, political regime change in the instance of countries choosing to withdraw from the Internet.
15) A table showing baseline demographic and clinical characteristics for each group
NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group
15-i) Report demographics associated with digital divide issues
subitem not at all importantessential Good point. N eligible to be exposed to intervention should also be indicated. This is a good principle, but too vaguely ...
16-ii) Primary analysis should be intent-to-treat
subitem not at all importantessential Comment on subitem 16-ii) Important to distinguish between effectiveness analyses (i.e. analysis of the whole sample) and efficacy analyses (i.e. sub-group analyses) which in the latter case is no longer a randomized sample. This should be made explicit in all papers. However, the intent-to-treat principle has its advantages, but also disadvantages. It seems to me that the statistical and methodological scientific community is becoming more and more pro imputation techniques because of the disadvantages associated with the ITT principle. Thus, I don't think that the primary analysis should or must be intent- 
19) All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)
19-i) Include privacy breaches, technical problems
Comment on subitem 19-ii)
It is time to slice the salami! A good quality qualitative paper is justified but a paragraph in the primary paper seems unlikely to adequately address the issues. With space limitations, this report would be limited in scope to 1 or 2 sentences. I do not think it should be required. Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Hmm . . . This really depends on the extent to which the qual data affected analysis and interpretation. In order to improve the website and make it more user friendly. It is very important as descriptiv ...
Add a subitem under CONSORT item 19
Maybe some guidelines about how to quantify qualitative feedback to make it more useful to others who may want to replicate the study -No.
DISCUSSION
22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group
22-i) Restate study questions and summarize the answers suggested by the data [2], starting with primary outcomes and process outcomes (use)
subitem not at all importantessential Comment on subitem 22-ii) Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses Essential I think mentioning the reproducibility of the intervention in other platforms is an appropriate suggestion for future research. This will provide direction and the the researcher's wisdom and perspective to the potential new researcher. Good point.
Is this not redundant?
This doesn't add much to the current version of CONSORT.
Add a subitem under CONSORT item 22
-It would be very useful if researchers could emphasize and elaborate on their lessons learned in the "design" and "implementation" of the intervention based on both primary and process outcome findings as well as unintended outcome findings. This information would be not only important for readers to see the actual picture of the intervention effects but also very beneficial to future researchers and developers so that the same lessons won't need to be learned again.
20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
20-i) Typical limitations in ehealth trials
24) Where the full trial protocol can be accessed, if available (no EHEALTH-specific subitems under CONSORT item 24)
An online database would be good. Contact
Authors.Best person to tell about the protocols used. No.
Agreed.
25) Sources of funding and other support (such as supply of drugs), role of funders (no EHEALTH-specific subitems under CONSORT item 25)
Yes, definitely, as part of sponsorships and conflict of interest disclosures Sources of funding and other support from businesses are so important in EHEALTH-specific
RCTs.
Whatever the case may be (in acknowledgements) No.
X27) (not a CONSORT item)
X27-i) State the "relation of the study team towards the system being evaluated" https://docs.google.com/spreadsheet/gform?key=0Aq_l0aMh4cwrdGZscXJBMGVRZDZWVjRSaWl0QzFVSFE&hl=en_US&gridId=0#chart
Comment on subitem X27-i)
As per the ISRII discussion -this is generally not explicity stated in face-to-face trials where it is a similar problem. Essential to allow for future comparisons across studies and allow the possibility of being part of meta-analyses As applicable. Vary from journal to journal.
Good point. Absolutely right.
Add a subitem under item X27
Maybe some more detail about what is meant by "system being evaluated." A list of key words would be good for purposes of future online database searching.
Last question
Do you want to become involved in the writing committee working on the elaboration document? If yes, please provide the subitems you wish to elaborate on 5-ii -developing a framework for a logical/process model 6a-i, 7a-i, 12a-i, 16-ii, X26 use: 5-ix, 5-xi, 6a-ii; differential attrition: 12a, 13b Possibly 4a-ii, 5viii, 5x, insertion of addition item in ...
Number of daily responses
